Inflammatory biomarkers, cerebral microbleeds, and small vessel disease: Framingham heart study

Neurology

Volumn 84, Issue 8, 2015, Pages 825-832

  Shoamanesh, Ashkan ^a,b   Preis, Sarah R ^c   Beiser, Alexa S ^c,d   Vasan, Ramachandran S ^d   Benjamin, Emelia J ^d   Kase, Carlos S ^d   Wolf, Philip A ^d   DeCarli, Charles ^e   Romero, Jose R ^d   Seshadri, Sudha ^d  

^a MCMASTER UNIVERSITY   (Canada)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^d BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CD40 LIGAND; ENDOCRINE GLAND DERIVED VASCULAR ENDOTHELIAL GROWTH FACTOR; FIBRINOGEN; HOMOCYSTEINE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; MYELOPEROXIDASE; OSTEOPROTEGERIN; PADGEM PROTEIN; PHOSPHOLIPASE A2; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 2; AUTACOID;

ADULT; AGED; ARTICLE; BRAIN HEMORRHAGE; BRAIN INFARCTION; CROSS-SECTIONAL STUDY; ENZYME ACTIVITY; FEMALE; FIBRINOGEN BLOOD LEVEL; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; BLOOD; CEREBRAL HEMORRHAGE; CEREBRAL SMALL VESSEL DISEASES; MASSACHUSETTS; MIDDLE AGED;

AGED; BIOMARKERS; CEREBRAL HEMORRHAGE; CEREBRAL SMALL VESSEL DISEASES; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; INFLAMMATION MEDIATORS; MALE; MASSACHUSETTS; MIDDLE AGED;

EID: 84923677640     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000001279     Document Type: Article

References (34)

1. Wardlaw JM, Smith C, Dichgans M. Mechanisms of sporadic cerebral small vessel disease: insights from neuroimaging. Lancet Neurol 2013;12:483-497
2. Koh SH, Park CY, Kim MK, et al. Microbleeds and free active MMP-9 are independent risk factors for neurological deterioration in acute lacunar stroke. Eur J Neurol 2011;18:158-164
3. Romero JR, Preis SR, Beiser AS, et al. Lipoprotein phospholipase A2 and cerebral microbleeds in the Framingham Heart Study. Stroke 2012;43:3091-3094
4. Feinleib M, Kannel WB, Garrison RJ, McNamara PM, Castelli WP. The Framingham Offspring Study: design and preliminary data. Prev Med 1975;4:518-525
5. Jefferson AL, Massaro JM, Wolf PA, et al. Inflammatory biomarkers are associated with total brain volume: the Framingham Heart Study. Neurology 2007;68:1032-1038
6. Pikula A, Beiser AS, Chen TC, et al. Serum brain-derived neurotrophic factor and vascular endothelial growth factor levels are associated with risk of stroke and vascular brain injury: Framingham Study. Stroke 2013;44:2768-2775
7. DeCarli C, Massaro J, Harvey D, et al. Measures of brain morphology and infarction in the Framingham Heart Study: establishing what is normal. Neurobiol Aging 2005;26:491-510
8. Pikula A, Beiser AS, DeCarli C, et al.Multiple biomarkers and risk of clinical and subclinical vascular brain injury: the Framingham Offspring Study. Circulation 2012;125:2100-2107
9. Greenberg SM, Vernooij MW, Cordonnier C, et al. Cerebral microbleeds: a guide to detection and interpretation. Lancet Neurol 2009;8:165-174
10. Romero JR, Preis SR, Beiser A, et al. Risk factors, stroke prevention treatments, and prevalence of cerebral microbleeds in the Framingham Heart Study. Stroke 2014;45: 1492-1494
11. Jeerakathil T, Wolf PA, Beiser A, et al. Stroke risk profile predicts white matter hyperintensity volume: the Framingham study. Stroke 2004;35:1857-1861
12. Shoamanesh A, Kwok CS, Benavente O. Cerebral microbleeds: histopathological correlation of neuroimaging. Cerebrovasc Dis 2011;32:528-534
13. Faustman D, Davis M. TNF receptor 2 pathway: drug target for autoimmune diseases. Nat Rev Drug Discov 2010;9:482-493
14. Pan W, Kastin AJ. Tumor necrosis factor and stroke: role of the blood-brain barrier. Prog Neurobiol 2007;83:363-374
15. Ferrero E, Zocchi MR, Magni E, et al. Roles of tumor necrosis factor p55 and p75 receptors in TNF-alphainduced vascular permeability. Am J Physiol Cell Physiol 2001;281:C1173-C1179
16. Fontaine V, Mohand-Said S, Hanoteau N, Fuchs C, Pfizenmaier K, Eisel U. Neurodegenerative and neuroprotective effects of tumor necrosis factor (TNF) in retinal ischemia: opposite roles of TNF receptor 1 and TNF receptor 2. J Neurosci 2002;22:RC216
17. Breckwoldt MO, Chen JW, Stangenberg L, et al. Tracking the inflammatory response in stroke in vivo by sensing the enzyme myeloperoxidase. Proc Natl Acad Sci USA 2008; 105:18584-18589
18. Vita JA, Brennan ML, Gokce N, et al. Serum myeloperoxidase levels independently predict endothelial dysfunction in humans. Circulation 2004;110:1134-1139
19. Yamada M, Itoh Y, Shintaku M, et al. Immune reactions associated with cerebral amyloid angiopathy. Stroke 1996; 27:1155-1162
20. Weiss R, Lifshitz V, Frenkel D. TGF-beta1 affects endothelial cell interaction with macrophages and T cells leading to the development of cerebrovascular amyloidosis. Brain Behav Immun 2011;25:1017-1024
21. Townsend KP, Town T, Mori T, et al. CD40 signaling regulates innate and adaptive activation of microglia in response to amyloid beta-peptide. Eur J Immunol 2005;35:901-910
22. Johnstone M, Gearing AJ, Miller KM. A central role for astrocytes in the inflammatory response to beta-amyloid; chemokines, cytokines and reactive oxygen species are produced. J Neuroimmunol 1999;93:182-193
23. Ballantyne CM, Hoogeveen RC, Bang H, et al. Lipoprotein-associated phospholipase A2, highsensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) Study. Arch Intern Med 2005;165:2479-2484
24. Wright CB, Moon Y, Paik MC, et al. Inflammatory biomarkers of vascular risk as correlates of leukoariosis. Stroke 2009;40:3466-3471
25. Van Campenhout A, Golledge J. Osteoprotegerin, vascular calcification and atherosclerosis. Atherosclerosis 2009;204: 321-329
26. Guldiken B, Guldiken S, Turgut B, et al. Serum osteoprotegerin levels in patients with acute atherothrombotic stroke and lacunar infarct. Thromb Res 2007;120:511-516
27. Castellanos M, Castillo J, Garcia MM, et al. Inflammationmediated damage in progressing lacunar infarctions: a potential therapeutic target. Stroke 2002;33:982-987
28. Giwa MO, Williams J, Elderfield K, et al. Neuropathologic evidence of endothelial changes in cerebral small vessel disease. Neurology 2012;78:167-174
29. Chang CY, Song MJ, Jeon SB, et al. Dual functionality of myeloperoxidase in rotenone-exposed brain-resident immune cells. Am J Pathol 2011;179:964-979
30. Pope SK, Kritchevsky SB, Ambrosone C, et al. Myeloperoxidase polymorphism and cognitive decline in older adults in the Health, Aging, and Body Composition Study. Am J Epidemiol 2006;163:1084-1090
31. Luo XG, Ding JQ, Chen SD. Microglia in the aging brain: relevance to neurodegeneration.Mol Neurodegener 2010;5:12
32. Menon RS, Burgess RE, Wing JJ, et al. Predictors of highly prevalent brain ischemia in intracerebral hemorrhage. Ann Neurol 2012;71:199-205
33. Shoamanesh A, Catanese L, Sakai O, Pikula A, Kase CS. Diffusion-weighted imaging hyperintensities in intracerebral hemorrhage: microinfarcts or microbleeds? Ann Neurol 2013;73:795-796
34. Jeon SB, Kwon SU, Cho AH, Yun SC, Kim JS, Kang DW. Rapid appearance of new cerebral microbleeds after acute ischemic stroke. Neurology 2009;73:1638-1644.